IL296892A - Interaction of sars-cov-2 proteins through a molecular or cellular mechanism of host cells and compounds for the treatment of covid -19 - Google Patents

Interaction of sars-cov-2 proteins through a molecular or cellular mechanism of host cells and compounds for the treatment of covid -19

Info

Publication number
IL296892A
IL296892A IL296892A IL29689222A IL296892A IL 296892 A IL296892 A IL 296892A IL 296892 A IL296892 A IL 296892A IL 29689222 A IL29689222 A IL 29689222A IL 296892 A IL296892 A IL 296892A
Authority
IL
Israel
Prior art keywords
cells
patient
cannabidiol
induction
apoptosis
Prior art date
Application number
IL296892A
Other languages
English (en)
Hebrew (he)
Original Assignee
Akseera Pharma Corp
Dr Merchant Shreema
Patel Manit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akseera Pharma Corp, Dr Merchant Shreema, Patel Manit filed Critical Akseera Pharma Corp
Publication of IL296892A publication Critical patent/IL296892A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL296892A 2020-03-29 2021-03-30 Interaction of sars-cov-2 proteins through a molecular or cellular mechanism of host cells and compounds for the treatment of covid -19 IL296892A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN202021013770 2020-03-29
IN202021030633 2020-07-18
IN202021054151 2020-12-12
PCT/IN2021/050325 WO2021199078A2 (en) 2020-03-29 2021-03-30 Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19.

Publications (1)

Publication Number Publication Date
IL296892A true IL296892A (en) 2022-12-01

Family

ID=77927896

Family Applications (1)

Application Number Title Priority Date Filing Date
IL296892A IL296892A (en) 2020-03-29 2021-03-30 Interaction of sars-cov-2 proteins through a molecular or cellular mechanism of host cells and compounds for the treatment of covid -19

Country Status (9)

Country Link
US (1) US20240226120A1 (OSRAM)
EP (1) EP4126913A4 (OSRAM)
JP (1) JP2023528561A (OSRAM)
CN (1) CN115968375A (OSRAM)
AU (1) AU2021247269A1 (OSRAM)
BR (1) BR112022019649A2 (OSRAM)
IL (1) IL296892A (OSRAM)
MX (1) MX2022012165A (OSRAM)
WO (1) WO2021199078A2 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3179022A1 (en) * 2020-07-18 2021-10-07 Akseera Pharma Corp. Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19
CN120789031A (zh) * 2020-07-24 2025-10-17 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备治疗冠状病毒感染的药物中的用途
CN115531315B (zh) * 2022-12-05 2023-04-07 上海惠盾因泰生物科技有限公司 重组人干扰素λ1鼻喷雾剂及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080043A1 (en) * 2002-03-18 2003-10-02 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
EP1559423A1 (en) * 2004-02-02 2005-08-03 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Medicinal acidic cannabinoids
US20130203715A1 (en) * 2010-07-20 2013-08-08 Pulmatrix, Inc. Use of trp channel agonists to treat infections
NL2009671C2 (en) * 2012-10-19 2014-04-23 Fytagoras B V New antiviral use for acidic cannabinoids.
US10456435B2 (en) * 2015-07-15 2019-10-29 Christopher A. MCELVANY Topical antiviral formulations and methods of using the same
WO2020257588A1 (en) * 2019-06-20 2020-12-24 Shaman Naturals, Llc Compositions for preventing and treating viral infections
CN115916336A (zh) * 2020-02-19 2023-04-04 施里玛·麦钱特 大麻二酚的组合物和治疗用途
US11338010B2 (en) * 2020-03-30 2022-05-24 Suzhou Kintor Pharmaceuticals, Inc. Systems, methods, and kits for diagnostics and treatment of viral respiratory infection
EP4149445A1 (en) * 2020-05-11 2023-03-22 ADD Advanced Drug Delivery Technologies, Ltd. Uses and formulations of cannabinoids
WO2021231810A1 (en) * 2020-05-14 2021-11-18 Augusta University Research Institute, Inc. Cannabidiol as a therapeutic modality for covid-19
CA3179022A1 (en) * 2020-07-18 2021-10-07 Akseera Pharma Corp. Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19
CN120789031A (zh) * 2020-07-24 2025-10-17 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备治疗冠状病毒感染的药物中的用途

Also Published As

Publication number Publication date
EP4126913A2 (en) 2023-02-08
WO2021199078A2 (en) 2021-10-07
AU2021247269A1 (en) 2022-12-01
WO2021199078A3 (en) 2021-12-09
CN115968375A (zh) 2023-04-14
JP2023528561A (ja) 2023-07-05
US20240226120A1 (en) 2024-07-11
MX2022012165A (es) 2023-01-24
EP4126913A4 (en) 2024-09-18
BR112022019649A2 (pt) 2022-12-27

Similar Documents

Publication Publication Date Title
US20240226120A1 (en) Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19
US20240024337A1 (en) Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19
Sadri Nahand et al. Virus, exosome, and MicroRNA: new insights into autophagy
JP2016041744A (ja) 抗ウイルス剤として用いられるｍＴＯＲキナーゼ阻害剤
Guo et al. Pyroptosis in glioma: current management and future application
KR20200131784A (ko) 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물
US12544388B2 (en) Compound for treating and/or preventing diseases caused by coronavirus and use thereof
CN113679726A (zh) 丹参提取物和醌类化合物在抗冠状病毒中的应用
US20230321126A1 (en) Micronutrient combination to inhibit coronavirus cell infection
JP2023516284A (ja) カンナビジオールの組成物および治療的使用
US20210315857A1 (en) Pharmaceutical micronutrient composition and its use to simultaneously inhibit multiple cellular mechanisms of infectivity caused by coronavirus, its variants and mutants
Silva et al. Autophagy modulators in coronavirus diseases: a double strike in viral burden and inflammation
US11273170B2 (en) Methods of treating cancer
Nabi-Afjadi et al. A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective? MN Afjadi et al.
Randhawa et al. Modulation of autophagy by SARS-CoV-2: a potential threat for cardiovascular system
Xu et al. Naringenin inhibits PRV replication by regulating the TLR4/NF-κB pathway mediated inflammatory response
Elkholy et al. Ivermectin: a closer look at a potential remedy
WO2021244481A1 (en) Compositions and methods for treating a sars-cov-2 infection
Luan et al. Mechanisms of the Mitochondrial Unfolded Protein Response in Caenorhabditis elegans and Mammals and Its Roles in Striated Muscles
Kandimalla et al. Exosome-mediated antiviral testing system and identification of Punicalagins and Anthocyanidins as promising antiviral agents against SARS-CoV-2
CA3195286A1 (en) Compositions and methods for treating acute respiratory failure and/or acute respiratory distress syndrome using tetrahydrocannabinol and compositions including same
Mahajan et al. Recent Advancements in the Delivery of Therapeutic Agents Targeting RNA-dependent RNA Polymerase of SARS-CoV-2
US20220323402A1 (en) Treatment, amelioration or prevention of a viral infection
Randhawa et al. Rappaport J and Gupta MK (2020) Modulation of Autophagy by SARS-CoV-2: A Potential Threat for Cardiovascular System
RU2843665C1 (ru) Фармацевтическая композиция для профилактики или лечения эпидемического рнк-вирусного инфекционного заболевания